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Endothelin-1 promotes cardiomyocyte hypertrophy by inducing
changesingeneexpression.ImmediateearlygenesincludingAtf3
(activating transcription factor 3), Egr1 (early growth response 1)
and Ptgs2 (prostaglandin-endoperoxide synthase 2) are rapi-
dly and transiently up-regulated by endothelin-1 in cardiomyo-
cytes. Atf3 regulates the expression of downstream genes and is
implicated in negative feedback regulation of other immediate
early genes. To identify Atf3-regulated genes, we knocked down
Atf3 expression in cardiomyocytes exposed to endothelin-1
and used microarrays to interrogate the transcriptomic effects.
The expression of 23 mRNAs (including Egr1 and Ptgs2)
was enhanced and the expression of 25 mRNAs was inhibited
by Atf3 knockdown. Using quantitative PCR, we determined
that knockdown of Atf3 had little effect on up-regulation of
Egr1 mRNA over 30 min, but abolished the subsequent decline,
causing sustained Egr1 mRNA expression and enhanced protein
expression. This resulted from direct binding of Atf3 to the
Egr1 promoter. Mathematical modelling established that Atf3
can sufﬁce to suppress Egr1 expression. Given the widespread
co-regulation of Atf3 with Egr1, we suggest that the Atf3–
Egr1 negative feedback loop is of general signiﬁcance. Loss
of Atf3 caused abnormal cardiomyocyte growth, presumably
resultingfromthedysregulationoftargetgenes.Theresultsofthe
present study therefore identify Atf3 as a nexus in cardiomyocyte
hypertrophy required to facilitate the full and proper growth
response.
Key words: activating transcription factor 3 (Atf3), early
growth response 1 (Egr1), hypertrophy, immediate early gene,
microarray, negative feedback.
INTRODUCTION
Cardiomyocytes, the terminally differentiated contractile cells
of the heart, undergo hypertrophy (i.e. increase in cell size)
in response to GqPCR (Gq-protein-coupled receptor) agonists
including ET-1 (endothelin-1) [1]. ET-1 particularly activates
the ERK1/2 (extracellular-signal-regulated kinase 1/2) cascade,
a pathway that is associated with cardiomyocyte hypertrophy
[1,2]. ERK1/2 signalling is strongly implicated in transcriptional
regulation and elicits many longer term effects through changes
in gene expression [3]. Perhaps unsurprisingly therefore, ∼70%
of the changes in gene expression induced in neonatal rat
cardiomyocytesovertheﬁrst4 hofstimulationwithET-1requires
ERK1/2 signalling [4–6]. However, activation of ERK1/2 in
cardiomyocytes by ET-1 is rapid and transient [7], and this
phase may be viewed as an initiating trigger of the longer term
response. Consistent with this, exposure of cardiomyocytes to
ET-1 results in multiphasic patterns of gene expression that
presumably culminate in hypertrophic growth [5]. Our previous
studiesidentiﬁedanumberofIEGs(immediateearlygenes;genes
that are regulated by pre-existing transcription factors) that are
particularly rapidly up-regulated in cardiomyocytes exposed to
ET-1 including Atf (activating transcription factor) 3 [5].
Atf3 is a member of the ATF/CREB [CRE (cAMP-response
element)-binding protein] family proteins which bind as homo-
or hetero-dimers to consensus ATF/CRE sites in gene promoters
to regulate transcription [8]. Like other members of this family,
full-length Atf3 possesses a bZIP (basic leucine zipper) domain
for dimerization, although alternative splicing can produce Atf3
isoformswithoutabZIPdomain.TheactivityofsomeATF/CREB
proteins is regulated by phosphorylation, but Atf3 is largely
regulated at the level of expression, being present at very low
levels in quiescent cells and induced as an IEG by a range
of extracellular stimuli (e.g. peptide growth factors, GqPCR
agonists and cytokines) and cellular stresses (e.g. oxidative stress
and ischaemia/reperfusion) in a variety of cell types. Indeed,
it is difﬁcult to identify a stimulus that does not induce Atf3
expression, suggesting that it plays a signiﬁcant global role
in regulating gene expression programmes. MAPKs (mitogen-
activated protein kinases) including ERK1/2 are particularly
implicated in promoting Atf3 mRNA expression, potentially
acting through a variety of transcription factors (e.g. CREB, Atf2
and c-Myc) [9–11]. Several studies also implicate the Egr1 (early
growth response 1) transcription factor in positive regulation of
Atf3 transcription, probably resulting from its phosphorylation
and activation by ERK1/2 [10,12,13].
Atf3 is generally viewed as a transcriptional repressor, particu-
larlywhenpresentashomodimers.ThusAtf3repressestranscrip-
tion of Gadd153 (growth arrest and DNA damage-inducible pro-
tein 153)/Chop10 [C/EBP (CCAAT/enhancher-binding protein)
Abbreviations used: AdV, adenovirus; Areg, amphiregulin; Atf, activating transcription factor; bZIP, basic leucine zipper; ChIP, chromatin
immunoprecipitation; CRE, cAMP-response element; CREB, CRE-binding protein; Dusp, dual speciﬁcity phosphatase; Egr1, early growth response
1; ERK1/2, extracellular-signal-regulated kinase 1/2; ET-1, endothelin-1; FDR, false discovery rate; Gapdh, glyceraldehyde-3-phosphate dehydrogenase;
GqPCR, Gq-protein-coupled receptor; HEK, human embryonic kidney; IEG, immediate early gene; IL, interleukin; Il1rl1, IL1 receptor-like 1; MAPK,
mitogen-activated protein kinase; MOI, multiplicity of infection; NF-κB, nuclear factor κB; qPCR, quantitative PCR; SNK, Student-Newman-Keuls; sqPCR,
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homologous protein 10]/DDIT3 (DNA-damage-inducible tran-
script 3 protein) and may also repress transcription from its
own promoter to limit expression [14]. A systems biology
study of TLR (Toll-like receptor) 4 signalling to gene
expression in macrophages further conﬁrmed its role as a
transcriptional repressor, demonstrating that Atf3 is induced by
lipopolysaccharide and represses expression of IL (interleukin)
6 and IL12b mRNAs by antagonizing NF-κB (nuclear factor
κB)-dependentstimulationoftranscription[15].Asimilarsystem
operates downstream from TLR9 [16], suggesting that negative
feedback regulation of cytokine production by Atf3 is a feature
of the innate immune response [17]. However, Atf3 (potentially
as heterodimers with other ATF/CREB proteins) promotes
transcription of other genes such as proglucagon [18]. Moreover,
in the context of DNA damage in cancer cells, Atf3 may act as a
positive regulator of gene expression, probably by enhancing p53
function [19]. The dichotomous role of Atf3 and the variation in
underlying mutations that cause cancer presumably account for
the variation in opinion regarding the role of Atf3 in this disease
[17].
As mentioned above, Atf3 is induced in cardiomyocytes by
ET-1 as an IEG [5], but it is also up-regulated in these cells by,
for example, doxorubicin [20], oxidative stress [3], insulin [21]
and hypoxia [22]. Transient ischaemia increases Atf3 expression
in whole hearts [22,23], and cardiospeciﬁc overexpression of
Atf3 in transgenic mice results in pathological features of cardiac
hypertrophy/failure [24] (this is distinguishable from, though
may encompass, cardiomyocyte hypertrophy [25]). Confusingly,
cardiac hypertrophy/failure induced by pressure overload is
exaggerated in Atf3-null mice [26]. This probably results from
enhanced signalling through ERK1/2 and other MAPKs, all of
whichareimplicatedinthedevelopmentofcardiacpathology[1].
Although these studies suggest that control of Atf3 expression
is important in homoeostatic control of cardiac function, it is
difﬁcult to develop a mechanistic understanding of Atf3 function
in these models with long-term manipulation of Atf3 expression.
WeusedthecardiomyocytemodeltoinvestigatetheroleofAtf3 in
negativefeedbackregulationofIEGexpressionandpositivefeed-
forward regulation of second-phase genes. Adopting an antisense
knockdown approach, we identiﬁed Egr1 as a prime target for
Atf3 repression in response to ET-1. Notably, Egr1 has been
associated with cardiac hypertrophy for many years [27–29],
and the results of the present study shed further light on the
transcriptional networks within which it operates.
EXPERIMENTAL
Cardiomyocyte cultures and knockdown of Atf3 with adenoviruses
for antisense Atf3
Ventricles from neonatal Sprague–Dawley rat hearts (Harlan)
were dissociated by serial digestion and cultured as described
previously [6]. For immunoblotting, RNA studies or ChIP
(chromatin immunoprecipitation), cardiomyocytes were plated in
15% (v/v) fetal bovine serum at a density of 4×10
6 cells/dish
on 60 mm Primaria dishes pre-coated with sterile 1% (w/v)
gelatin (Sigma–Aldrich). For immunostaining experiments, glass
coverslips were placed in Primaria 35 mm culture dishes and
coated with 1% (v/v) gelatin then laminin (0.2 mg/ml in PBS,
2 h). Coverslips were washed with PBS. Cardiomyocytes were
plated at 1.5×10
6 cells/dish in serum-containing medium. After
18 h, cardiomyocytes were incubated in serum-free medium
for 24 h then unstimulated (controls) or exposed to 100 nM
ET-1 (Bachem) in the presence or absence of cycloheximide
(Sigma–Aldrich), U0126 or PD184352 (Enzo Life Sciences).
Agonists/inhibitors were prepared as 1000× stock solutions in
water (ET-1, cycloheximide) or DMSO (U0126, PD184352) and
added directly to the tissue culture medium.
Preparation of AdVs (adenoviruses)
Replication-deﬁcient AdVs expressing full-length rat Atf3
antisense RNA (AS-Atf3) were prepared using the AdEasy
TM XL
Adenoviral Vector System (Stratagene). The coding sequence for
Atf3 was isolated by PCR from rat cardiomyocyte cDNA using
Pfupolymeraseandprimersdesignedtothe5
  startsite(5
 -ATGA-
TGCTTCAACATCCAGGC-3
 )a n d3
  stop codon (5
 -TTAG-
CTCTGCAATGTTCCTTC-3
 ) regions, and further ampliﬁed
with primers that included sites for restriction enzymes
HindIII (5
 -CTTATCTAGAAGCTTATGATGCTTCAACATCC-
AGGC-3
 ) and KpnI (5
 -TAGAGATCTGGTACCTTAGCTCTG-
CAATGTTCCTTC-3
 ) for insertion into the multiple cloning site
of the pShuttle-CMV vector. Control samples were prepared with
empty vector (No-AS). Constructs were sequenced using an ABI
3100 Genetic Analyser. Shuttle plasmids were linearized with
PmeI and used to transform BJ5183-AD-1 cells. AdV plasmids
from positive recombinants were expanded in XL10Gold cells,
linearized with PacI and used to transform HEK (human
embryonic kidney)-293 cells. AdVs were ampliﬁed through
subsequent re-infection of HEK-293 cells and titres were
determined using Adeno-X
TM Rapid Titer kits (Clontech). For
experiments with AdVs, cardiomyocytes were incubated in
serum-free medium for 4 h, AdVs were added and the cells
incubated for a further 48 h.
Immunoblotting
Cardiomyocytes were washed in ice-cold PBS and nuclear
extracts prepared for immunoblotting as described previously
[30]. Proteins (20 μg) were separated by SDS/PAGE (10% or
12%gels)andtransferredelectrophoreticallyontonitrocellulose
membranes. Immunoblotting was performed as described
previously [5]. Primary antibodies against Atf3 (sc-188), Egr1
(sc-189) and Atf2 (sc-187) were from Santa Cruz Biotechnology
and used at a 1/1000 dilution. Secondary antibodies conjugated
to horseradish peroxidase were from Dako (1/5000 dilution).
Bands were detected using ECL (enhanced chemiluminescence)
Plus with an ImageQuant 350 digital imager (GE Healthcare).
ImageQuant 7.0 software was used for densitometric analysis.
RNA preparation, microarrays and data analysis
Cardiomyocytes were uninfected or infected with empty AdVs
or AdVs encoding AS-Atf3 and then unstimulated (controls) or
exposed to 100 nM ET-1 (90 min). Uninfected cardiomyocytes
were exposed to ET-1 for 30, 60 or 90 min. Total RNA
was prepared and concentrations determined as described
previously [5]. To minimize the variation resulting from different
cardiomyocyte preparations, equal amounts of RNA from three
individual experiments were pooled to generate a single sample
set. A total of three sets of pooled samples were prepared for
hybridization to separate Affymetrix rat exon 1.0 ST arrays
(i.e. three separate sets of samples were analysed for each
condition, prepared from a total of nine myocyte preparations).
Samples were prepared for hybridization using Genechip® WT
Sense Target Labelling kits (Affymetrix). For all samples,
except those from uninfected cells exposed to ET-1 for 60 min
with their corresponding controls, the rRNA reduction protocol
was modiﬁed and the RiboMinus Transcriptome Isolation
Kit (Human/Mouse) (Invitrogen) was used according to the
manufacturer’s instructions with 7 μg of RNA. Hybridization to
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Affymetrix rat exon 1.0 ST arrays was performed at the CSC/IC
Microarray Centre (Imperial College London, London, U.K.).
For samples from uninfected cells exposed to ET-1 for 60 min
with their corresponding controls, total RNA was provided to the
European Arabidopsis Stock Centre at Nottingham (NASC) for
preparation and hybridization to Affymetrix rat exon 1.0 arrays
according to their protocols (http://affymetrix.arabidopsis.info).
The results are available from ArrayExpress (accession numbers
E-MEXP-3392, E-MEXP-3393 and E-MEXP-3394).
The data (.CEL ﬁles) were imported into GeneSpring
11.5 (Agilent Technologies) using the Extended annotations,
with RMA16 normalization and normalization per gene to
corresponding uninfected unstimulated controls within each
sample set. Probesets were selected for analysis with baseline
expression >50 in all of any of the conditions. To determine
effects of AdV infection, probesets were selected with >1.5-
fold change in unstimulated cells infected with No-AS AdVs
relative to uninfected cells, applying an unpaired Student’s t test
with the Benjamini and Hochberg multiple testing correction
[FDR (false discovery rate)<0.05)]. To identify transcripts
regulated by Atf3, we selected those which were signiﬁcantly
changed (>1.5-fold; FDR<0.05) in uninfected cells in response
to ET-1 at 30, 60 or 90 min (unpaired Student’s t tests with
the Benjamini and Hochberg multiple testing correction). For
transcripts with <1.2-fold change in baseline expression with
No-AS AdVs, subsequent analysis employed an interpretation
with AdV-infected conditions, using statistical testing [one-
way ANOVA with SNK (Student-Newman-Keuls) post-test and
BenjaminiandHochbergmultipletestingcorrection]andﬁltering
onthebasisof>1.5-folddifferencebetweenAS-Atf3andNo-AS
infected cells. For transcripts with >1.2-fold change in baseline
expression with No-AS AdVs, subsequent analysis employed an
interpretation with all conditions, using statistical testing (one-
wayANOVAwithSNKpost-testandtheBenjaminiandHochberg
multiple testing correction) to identify mRNAs with signiﬁcant
difference between cells infected with AS-Atf3 and No-AS AdVs
or uninfected cells, but with no signiﬁcant difference between
uninfected cells and those infected with No-AS AdVs with
exposure to ET-1 (90 min) and/or in unstimulated cells. Further
ﬁltering identiﬁed transcripts with >1.5-fold difference between
cells infected with AS-Atf3 and those infected with No-AS AdVs
or uninfected cells.
PCR
Cardiomyocytes were treated and total RNA extracted as
for microarray analysis. cDNAs were synthesized using High
Capacity cDNA Reverse Transcription Kits with random primers
(Applied Biosystems). sqPCR [semi-qPCR (quantitative PCR)]
and qPCR were performed as described previously [5] using
primers listed in Supplementary Table S2 (at http://www.
BiochemJ.org/bj/444/bj4440343add.htm). Values were normal-
ized to Gapdh (glyceraldehyde-3-phosphate dehydrogenase)
expression and then to control values.
ChIP
Cardiomyocytes (16×10
6 cells per sample) were unstimulated
or exposed to 100 nM ET-1 and ﬁxed in 1% (v/v) form-
aldehyde (10 min). The reaction was terminated with 125 mM
glycine (10 min). Cells were washed and harvested in ice-cold
PBS containing protease/phosphatase inhibitors [5], collected
by centrifugation (3000 g at 4◦C for 5 min) and lysed
(15 min at 4◦C) in 50 mM Tris/HCl (pH 8.0), 2 mM EDTA,
0.1% Nonidet P40 and 10% (v/v) glycerol containing
protease/phosphatase inhibitors. Nuclei were pelleted (3000 g
at 4◦C for 5 min), resuspended in 50 mM Tris/HCl (pH 8.0),
1% (w/v) SDS and 5 mM EDTA, and the DNA sheared
to 200–800 bp fragments by sonication (5×30 s with 2 min
recovery at 4◦C). Following centrifugation (4000 g at 4◦C
for 5 min), the supernatants were retained and a sample
reserved for input DNA. The remainder was diluted in 50 mM
Tris/HCl (pH 8.0), 0.5% Nonidet P40, 200 mM NaCl and
0.5 mM EDTA. Samples were pre-cleared with Protein A–
Sepharose then incubated without or with 0.01 mg of anti-Atf3
antibodies (Santa Cruz Biotechnology, catalogue number sc-
188X) with rotation (overnight at 4◦C). Protein A–Sepharose
was added together with sonicated salmon sperm DNA (1 μg/ml)
and samples were incubated (4◦C for 2 h). Beads were pelleted
by centrifugation (1000 g at 4◦C for 3 min) and washed (4◦C
for 3 min) in 20 mM Tris/HCl (pH 8.0), 0.1% SDS, 1% (v/v)
NonidetP40,2 mMEDTAand500 mMNaClfollowedby10 mM
Tris/HCl (pH 8.0) containing 1 mM EDTA. Immune complexes
were eluted (10 min at 65◦C) in 10 mM Tris/HCl (pH 8.0), 1 mM
EDTA and 1% (w/v) SDS. Samples were centrifuged (200 g for
1 min) and the supernatants collected. Cross-links were reversed
by incubation (overnight at 65◦C) with 0.2 M NaCl. Samples
were incubated (5 min at 4◦C) with phenol/chloroform/3-
methylbutan-1-ol (25:24:1, pH 8.0) and the phases separated by
centrifugation (15300 g at 4◦C for 10 min). DNA in the upper
aqueous phase was precipitated with isopropanol (−80◦Cf o r
3 h), recovered by centrifugation (15300 g for 10 min at 4◦C),
washed [70% (v/v) ethanol] and resuspended in nuclease-free
water for PCR. PCR reactions were performed using speciﬁc
primers: Egr1 forward, 5
 -ACTGCCGCTGTTCCAATACT-3
 ;
Egr1 reverse, 5
 -CGAATCGGCCTCTATTTCAA-3
 ;P t g s 2
forward, 5
 -GCAGCAAGCACGTCAGACT-3
 ; Ptgs2 reverse, 5
 -
TAACCCGGAGAACCTTGCTT-3
 ; IL6 forward, 5
 -TGCTCA-
AGTGCTGAGTCACT-3
 ; IL6 reverse, 5
 -AGACTCATGG-
GAAAATCCCA-3
 . The primers for an arbitrary downstream
sequence ∼2000 bp 3
  to the IL6 promoter were: for-
ward, 5
 -CACCTCTCCACCCTGACATT-3
  and reverse, 5
 -
CCAACTAGACAGCCCAGAGC-3
 . PCR ampliﬁcation condi-
tions were: 34 cycles of denaturing at 95◦C for 30 s, annealing at
60◦C for 30 s and extension at 72◦C for 45 s. PCR products were
visualized on 2% (w/v) agarose gels with Sybr-Safe (Invitrogen)
and the bands captured under UV illumination. Densitometric
analysis was performed using Imagemaster 1D Prime, version
3.0 (GE Healthcare).
Immunostaining
Cardiomyocytes were exposed to 100 nM ET-1, then washed
with PBS and ﬁxed in 4% (v/v) formaldehyde [10 min at
room temperature (25◦C)]. Immunostaining was performed as
described previously [31] using mouse monoclonal primary
antibodies against troponin T (1/40 dilution for 60 min;
Stratech Scientiﬁc, catalogue number MS-295-P1) and Alexa
Fluor® 488 anti-mouse secondary antibodies (1/200 dilution
for 60 min). Coverslips were mounted using ﬂuorescent
mounting medium (Dako) and viewed using a Zeiss Axioskop
ﬂuorescence microscope. Images were captured using a digital
camera (1600×1200 pixels resolution, ×1.4 zoom factor and
160×120 μm ﬁeld dimension). Colour images were converted
to greyscale using Adobe Photoshop.
Statistical analysis
Statistical analysis of microarray data used GeneSpring 11.5.
Other analyses used GraphPad Prism 4.0.
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Figure 1 Atf3 mRNA and protein is increased in cardiomyocytes exposed to ET-1 and suppressed by AS-Atf3
Cardiomyocytes were unstimulated (control) or exposed to 100nM ET-1 for the times indicated (A), were exposed for 0.5 h to 20μM cycloheximide (CHX), or 10μM U0126, ET-1, or
ET-1 in the presence of CHX or U0126 (B) or were exposed to ET-1 in the absence or presence of 2μM PD184352 (C). RNA was extracted and Atf3 mRNA expression measured by sqPCR
(A and B)o rq P C R( A and C). For (A)a n d( B) the representative sqPCR images are for Atf3 (upper image, 388bp amplicon) and Gapdh (lower image, 412bp amplicon). Positions of markers are
shown on the left-hand side and controls with no reverse transcriptase (RT) were negative. Densitometric analysis for sqPCR of Atf3 is shown in the lower panels. In (A) sqPCR and qPCR data
are compared and results are a range from 0 (control values) to 1 (maximal expression at 0.5 h). All data were normalized to Gapdh and are means+ −S.E.M. for three or four myocyte preparations.
(D) Cardiomyocytes were exposed to ET-1 for the times indicated and nuclear extracts (20μg of protein) immunoblotted with antibodies against Atf3 using 12% polyacrylamide gels. Atf3 was
detected as a band of ∼ 21kDa. A representative image is shown (upper panel) with densitometric analysis (lower panel). Results are mean + −S.E.M. for three myocyte preparations. (E–G)
Cardiomyocytes were infected with No-AS or AS-Atf3 AdVs at the indicated MOI and unstimulated (control) or stimulated with 0, 10 or 100nM ET-1. Nuclear extracts were immunoblotted for Atf3
using 12% (E and F)o r1 0%( G) polyacrylamide gels. In (G) the blots were divided into upper and lower sections and were probed with antibodies against Atf2 and Atf3 respectively. Atf2 was
detected at ∼70kDa. @P <0.05 relative to ET-1; *P <0.001 relative to control; **P <0.01 relative to control; #P <0.001 relative to ET-1 (one way ANOVA with SNK post-test). In all of the gels,
the positions of relative molecular mass markers are given in kDa on the left-hand side.
RESULTS
Regulation of Atf3 expression in cardiomyocytes by ET-1 and
identiﬁcation of Atf3 target genes
ET-1 (100 nM) stimulated a rapid transient increase in expression
of Atf3 mRNA in cardiomyocytes (Figure 1A). Expression was
maximal within 30 min, declining rapidly thereafter. Cyclohex-
imide (a protein synthesis inhibitor) did not inhibit the response,
indicating that Atf3 was regulated as an IEG (Figure 1B), and
up-regulation of Atf3 mRNA by ET-1 was inhibited by U0126
or PD184352, inhibitors of the ERK1/2 cascade (Figures 1B and
1C). Atf3 protein was also increased by ET-1 (maximal at 1 h)
(Figure 1D). To suppress expression of Atf3, we generated AdVs
encoding full-length Atf3 in the antisense orientation (AS-Atf3),
usingemptyAdVswithnoAS-Atf3(No-AS)tocontrolforeffects
of viral infection. Effective knockdown of Atf3 protein induced
by ET-1 was obtained using 150 MOI (multiplicity of infection)
AS-Atf3 AdVs with limited effect of No-AS AdVs and no effect
on expression of Atf2 (Figures 1E–1G).
Uninfected cardiomyocytes or cardiomyocytes infected with
150MOI No-AS or AS-Atf3 AdVs were unstimulated or exposed
to 100 nM ET-1 for 90 min (since expression of Atf3 protein was
maximal at 1 h, we expected to detect downstream consequences
by 90 min; Figure 1D) and mRNA expression proﬁling was
performed(Affymetrixratexon1.0STmicroarrays).Asexpected,
No-ASAdVinfectionalonesigniﬁcantly(>1.5-fold;FDR<0.05)
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Figure 2 Infection with AdVs modulates expression of a subset of cardiomyocyte mRNAs
Cells (uninfected or infected with 150 MOI No-As or AS-Atf3) were unstimulated or exposed to ET-1 for 90min and RNA expression proﬁles determined using Affymetrix rat exon 1.0 ST arrays.
(A) Heatmaps show expression proﬁles for probesets that were signiﬁcantly changed (>1.5-fold, FDR < 0.05) by viral infection alone. Normalization is to the gene median [range is −2.5 (cyan)
through 0 (black) to +2.5 (red) on a log2 scale]. Results are means for three hybridizations each representing three independent myocyte preparations. Clustering on conditions and entities used a
Euclidean distance matrix and centroid linkage ratio. (B) Transcripts were classiﬁed according to function. Up- and down-regulated transcripts are in red and blue respectively. Transcripts regulated
by interferons (Ifn) in other systems are in lighter colours.
affected expression of a subset of mRNAs (156 mRNAs
up-regulated and 59 mRNAs down-regulated), many of which
are associated with a viral response and/or cytokine/chemokine
signalling in other cells (Figure 2 and Supplementary Table S3 at
http://www.BiochemJ.org/bj/444/bj4440343add.htm).
To determine the effects of Atf3 in the ET-1-responsive
myocyte transcriptome, probesets were selected with signiﬁcant
changes in expression (>1.5-fold, FDR<0.05) induced by ET-1
at 30, 60 or 90 min (334 up-regulated and 109 down-regulated
mRNAs). From these, we identiﬁed 90 mRNAs that were up-
regulated by ET-1 and affected by Atf3 knockdown (Figure 3A
and Supplementary Tables S4–S6 at http://www.BiochemJ.org/
bj/444/bj4440343add.htm). Of the up-regulated transcripts
without a baseline effect of viral infection (75 mRNAs),
AS-Atf3 enhanced the response of 15 mRNAs (clusters A1
and A2), inhibited the response of 18 mRNAs (clusters B1 and
B2) and, for 42 mRNAs (cluster C), AS-Atf3 enhanced
the response in unstimulated cells without further effect on the
response to ET-1. Of the up-regulated mRNAs with a baseline
effect (>1.2-fold change) of viral infection, the response to ET-1
was enhanced or inhibited by AS-Atf3 for eight (cluster D) or
seven(clusterE)mRNAsrespectively.WithET-1-down-regulated
mRNAs (Figure 3B and Supplementary Table S7 at http://www.
BiochemJ.org/bj/444/bj4440343add.htm), we identiﬁed only ﬁve
mRNAs for which AS-Atf3 reduced the magnitude of the down-
regulation by ET-1 (cluster F) and ﬁve mRNAs for which
AS-Atf3 increased the magnitude of the response (cluster G).
HavingpreviouslydeﬁnedIEGscomparedwithdownstreamgene
expression for mRNAs up-regulated by ET-1 (Affymetrix rat
genome 230 2.0 arrays) [5], we cross-referenced the datasets
(Supplementary Tables S4 and S6). A greater proportion of
mRNAs in clusters A1, A2 and D (Atf3-knockdown-enhanced
ET-1-induced expression) were IEGs rather than second-phase
genes, consistent with negative feedback by Atf3. A greater
proportion of mRNAs in clusters B1 and B2 (Atf3-knockdown-
inhibited ET-1-induced expression) were second-phase genes
rather than IEGs, suggesting that Atf3 plays a positive feed-
forward role in these cases (genes in cluster E were not identiﬁed
in the previous dataset [5]). Overall, we conclude that up-
regulation of Atf3 by ET-1 in cardiomyocytes plays a signiﬁcant
role in modulating the response of other up-regulated genes and
a minor role in regulating mRNAs that are down-regulated by
ET-1.
Negative regulation of Egr1 and Ptgs2 expression by Atf3
Microarray data were validated by qPCR, selecting IEGs with
enhanced expression of the ET-1 response by AS-Atf3 (Egr1
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Figure 3 Atf3 knockdown modulates the response of the cardiomyocyte transcriptome to ET-1
Cardiomyocytes were uninfected or infected with No-AS or AS-Atf3 AdVs (150 MOI), then were unstimulated (control) or exposed to ET-1 (100nM for 90min). RNA was extracted and analysed
using Affymetrix rat exon 1.0 ST arrays. Analysis of transcripts that were up- (A) or down-regulated (B) by ET-1 identiﬁed mRNAs that were signiﬁcantly changed (>1.5-fold, FDR<0.05) by AS-Atf3
compared with No-AS or uninfected cells in the absence (clusters, A, B, C and F) or presence (clusters D, E and G) of a statistically signiﬁcant baseline effect (>1.2-fold) of viral infection as
determined by GeneSpring analysis (P <0.05). mRNAs were clustered as indicated. Heatmaps are shown for each cluster with normalization to uninfected controls [range is −2.5 (cyan) through
0 (black) to +2.5 (red) on a log2 scale]. Results are means for three hybridizations each representing three independent myocyte preparations. Clustering on entities used a Euclidean distance
matrix and centroid linkage ratio. Histograms are means+ −S.E.M. for the relative mRNA expression for each cluster. Each cluster was subjected to further statistical analysis independently of the
global-GeneSpringanalysis.*P <0.001relativetoNo-ASET-1;**P <0.05relativetoNo-ASET-1;#P <0.001relativetoNo-AScontrol;##P <0.05relativetoNo-AScontrol;@P <0.05relative
to no virus control (one-way ANOVA with SNK post-test). Although the No-AS effect in control cells is signiﬁcant in the context of global statistical testing of microarray data, with the small numbers
ofgenesinclustersDandE(withthevariationinexpressionlevels)thiswasnotsigniﬁcantwithsecondarytesting.Similarly,forclusterD,althoughtheAS–Atf3controldataaresigniﬁcantlydifferent
from the no-virus control, they are not statistically signiﬁcantly different from the No-AS control.
and Ptgs2) and non-IEGs with reduced expression by AS-Atf3
[Areg (amphiregulin) and Dusp (dual speciﬁcity phosphatase) 5]
for analysis. For Egr1 and Ptgs2, the relative increase in ex-
pression induced by ET-1 at 0.5 h was similar in cardiomyocytes
expressing No-AS or AS-Atf3 (Figures 4A and 4B), indicating
that Atf3 was not involved in this up-regulation phase. AS-Atf3
produced sustained expression of Egr1 mRNA (Figure 4A) and
enhanced expression of Ptgs2 at subsequent times (Figure 4B),
consistent with negative feedback of Atf3 on these two genes. In
contrast, AS-Atf3 inhibited expression of Areg (Figure 4C) and
Dusp5 (Figure 4D). The qPCR data (Figure 4, left-hand panels)
are consistent with the microarray results (Figure 4, right-hand
panels). Dusp1 (an IEG) and Il1rl1 (IL1 receptor-like 1; a non-
IEG)werenotsigniﬁcantlyaffectedbyAS-Atf3 inourmicroarray
experiments and there was no difference in the relative changes
in expression induced by ET-1 in cardiomyocytes expressing
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Figure 4 qPCR validation of microarray data
Results were validated for Egr1 (A), Ptgs2 (B), Areg (C), Dusp5 (D), Dusp1 (E), Il1rl1 (F)a n d
IL6 (G). Left-hand panels: cardiomyocytes were infected with No-AS ( and broken line) or
AS-Atf3(andsolidline)AdVs,thenexposedto100nMET-1forthetimesindicated.RNAwas
extracted and expression of mRNAs analysed by qPCR. Results are means+ −S.E.M. for three
myocytepreparations.*P <0.05forAS-Atf3relativetoNo-ASatthesametimepoint(one-way
ANOVA with SNK post-test). Right-hand panels: microarray data for each of the mRNAs studied
are presented relative to uninfected (NV) controls. Results are shown for unstimulated cells
(open bars) and cardiomyocytes exposed to ET-1 for 90min (ﬁlled bars). Results are means for
three independent myocyte preparations and hybridizations.
No-AS or AS-Atf3 (Figures 4E and 4F). Thus our selection
criteria were not excessively stringent. Finally, although others
have identiﬁed IL6 as a target for negative feedback by
Atf3 in the context of inﬂammation [15], there was no
difference in relative expression of IL6 mRNA in cardiomyocytes
expressing No-AS or AS-Atf3 following stimulation with ET-
1 at any time studied (Figure 4G). To validate the Atf3–
Egr1 feedback loop further, we examined the effect of AS-
Atf3 on Egr1 protein expression following induction with ET-
1. AS-Atf3 (but not No-AS) inhibited expression of Atf3 for
the 150 min period studied (Figures 5A and 5B). AS-Atf3 did
not substantially increase the total amount of Egr1 protein at
60 min,butlevelsremainedelevatedupto∼105 min(Figures5A
and5C).AfterthistimeEgr1proteindeclined,butlevelsremained
elevated up to at least 150 min.
ChIPwithantibodiesagainstAtf3wasusedtodetermineifAtf3
bindsdirectlytotheEgr1andPtgs2promoters.TheEgr1promoter
contains two CRE elements [32], and a CRE element potentially
subject to negative regulation by Atf3 has been identiﬁed in the
Ptgs2 promoter [33,34]. We used primers either side of these
sequencesforChIP–PCR(Figures6Aand6C).Forbothgenes,the
amount of ChIP–PCR product in unstimulated cells was similar
to that of the no-antibody controls and stimulation with ET-1
(1 h) substantially increased the amount of ChIP–PCR product
(Figures 6B and 6D). Thus Atf3 binds directly to Egr1 and
Ptgs2 promoters to inhibit transcription. Interestingly, ChIP–PCR
for the IL6 promoter (Figure 6E) demonstrated binding of Atf3
(Figure 6F) despite there being no effect of Atf3 knockdown on
expressionofIL6mRNA(Figure4G).Thisisdiscussedbelow,but
potentially results from ET-1 signalling through ERK1/2 rather
than NF-κB. The speciﬁcity of the ChIP–PCR experiments was
demonstratedbyPCRacrossanarbitrarysequenceapproximately
2000 bp downstream of the IL6 promoter (Figure 6G).
Mathematical modelling of the Atf3–Egr1 negative feedback loop
Atf3 appears to be a dominant-negative regulatory factor in
suppressing Egr1 transcription (Figure 4A), but we cannot
eliminate the possibility of additional negative regulatory
elements from the experimental data. We therefore developed
a deterministic ordinary differential equation model for the Atf3–
Egr1 feedback system (Figure 7A) to determine whether Atf3 ex-
pression can sufﬁce to suppress Egr1 transcription. We
assumed the following: Atf3 and Egr1 are co-regulated
through ERK1/2 signalling (expression of each requires a
similar degree of ERK1/2 signalling [5]); ERK1/2 promote
expression by increasing transactivating activities of transcription
factors pre-bound to both promoters (i.e. the transcription factor/
promoter is viewed as a single entity regulated by ERK1/2
binding/phosphorylation); and it was not necessary to consider
ERK1/2 or Atf3 signal termination (i.e. no attempt was made
to switch off the signal). The model was informed initially by
parameters derived in the present study and from previously
published literature (see the Supplementary Online Data at
http://www.BiochemJ.org/bj/444/bj4440343add.htm).
We initially assumed that Atf3 suppression of Egr1 mRNA
transcription was competitive with the positive ERK1/2 signal,
but this did not give a good ﬁt with the experimental data. An
alternative model in which Atf3 eliminates the ERK1/2 signal
(modelled by removing the ERK1/2 signal upon Atf3 binding;
Figure 7A) gave a good qualitative ﬁt. Adjusting the rate of
mRNA synthesis to 275 bases/s (within the recently estimated
rangeof55to>800bases/s[35,36])forcalculationoftheratesof
transcription of Egr1 and Atf3 mRNAs, and adjusting parameters
for association of phosphorylated ERK1/2 with Egr1 and Atf3
DNA (see the Supplementary Online Data) gave a very good
ﬁt to the experimental data in terms of magnitude of variation
in Egr1 mRNA (∼20-fold; Figure 4A), and a relatively good
ﬁt (qualitatively) to the suppression of Egr1 mRNA by Atf3. The
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Figure 5 AS-Atf3 expression enhances expression of Egr1 protein in cardiomyocytes exposed to ET-1
Cardiomyocytes were uninfected or were infected with No-AS ( and broken line) or AS-Atf3 ( and solid line) AdVs, then exposed to 100nM ET-1 for the times indicated. (A) Nuclear extracts
(20μg of protein) were immunoblotted for Egr1 (upper images) or Atf3 (lower images). Representative blots of the same nuclear extracts are shown. Positions of relative molecular mass markers
are given in kDa on the left-hand side. (B) Densitometric data for expression of Atf3 protein. (C) Densitometric data for expression of Egr1 protein. Results were normalized to the no-virus samples
on each blot and are means+ −S.E.M. for three myocyte preparations. *P <0.05 for AS-Atf3 relative to No-AS at the same time point (one-way ANOVA with SNK post-test).
best-ﬁtmodelwasobtainedwitharateofAtf3suppressionofEgr1
transcription (k7) in the range 1×10
5(Ms)
−1 k76×10
5(Ms)
−1
(Figure 7B). Modelling the system in the absence of Atf3 (to
mimic Atf3 knockdown) resulted in a similar rate of production
of Egr1 mRNA to ∼0.5 h, with sustained expression thereafter
(Figure 7B, centre left-hand panel), a proﬁle that replicates the
experimental data (Figure 4A, left-hand panel). Thus Atf3 alone
can account for the suppression of Egr1 mRNA expression and
probably does so by over-riding the positive ERK1/2 signal.
Effects of Atf3 on morphological changes induced in
cardiomyocytes by ET-1
To determine the consequences of knockdown of Atf3 for ET-1-
induced hypertrophy, we examined the effects of AS-Atf3 AdVs
on myocyte morphology by immunostaining for troponin T, a
component of the myoﬁbrillar apparatus. As shown previously
[37,38], uninfected and unstimulated cardiomyocytes appear
small with disorganized myoﬁlaments (Figure 8A). Stimulation
with ET-1 increased cell size, increased the content/organiz-
ation of myoﬁlaments and promoted formation of cell–cell
contacts (Figure 8B), classic features of hypertrophy. No-AS
AdVs increased myoﬁbrillar content to a small degree in
unstimulated cells (Figure 8C), but had no overt effect on
morphological changes induced by ET-1 (Figure 8D). Relative to
No-ASAdVs,AS-Atf3AdVshadnoeffectonunstimulatedcells,
but resulted in abnormal morphology following ET-1 stimulation
with ‘clumping’ of cells and generation of elongated processes
extendingbetweenthem(Figures8E–8H).Itisunclearifthisisan
effect on hypertrophy itself or whether there is a loss of cell–cell
or cell–matrix adhesion. Thus, although Atf3 is transiently up-
regulated within the ﬁrst hour of stimulation, it has a signiﬁcant
effect on long-term phenotypic changes.
DISCUSSION
Atf3 is emerging as an extremely important feedback regulator
of transcription in general. Greatest emphasis has been placed
on its role in inﬂammation and it is clear that Atf3 is essential
for restraining the immune response [15,17]. However, although
viewed as a stress-regulated and -regulatory gene, Atf3 is also
up-regulated in many cells by growth stimuli including peptide
growth factors and GqPCR agonists [5,39–41]. The genes that
Atf3 regulates in a growth context are likely to differ from those
that it regulates in a stress response. In the present study, we
identiﬁed a number of genes that are regulated in cardiomyocytes
in response to ET-1 for which Atf3 plays either a negative
feedback or positive feed-forward role (Figure 3). Since loss of
Atf3 results in a severely abnormal response to ET-1 (Figure 8),
strict regulation of any or all of these targets must be important in
ensuring an appropriate hypertrophic growth response. However,
ofallthepotentialtargets,Egr1emergedasasigniﬁcantcandidate
and we provide substantial evidence that Atf3 is a transcriptional
repressor for Egr1 in the ET-1 response. Thus Atf3 knockdown
leads to sustained expression of Egr1 mRNA and enhanced
expression of Egr1 protein, and Atf3 binds directly to the Egr1
promoter. Furthermore, mathematical modelling of the system
established that Atf3 alone can sufﬁce to suppress Egr1 mRNA
expression.
Egr1 was among the ﬁrst IEGs to be identiﬁed [42] and
it is up-regulated in many cells in response to a wide
range of growth stimuli [43]. As such, it is implicated in
a host of different systems including kidney differentiation
[44], macrophage differentiation [45], the nervous system and
learning/memory [46,47], the immune response [48], wound
healing and tissue repair [49], prostate cancer [50] and acute
lung injury [51]. In the vascular system, Egr1 is associated with
excessive smooth muscle cell proliferation resulting in in-stent
restenosis following angioplasty [52]. Egr1 is also implicated
in cardiac/cardiomyocyte hypertrophy. Thus expression of Egr1
is increased in cardiomyocytes and the heart in response to a
varietyofhypertrophicstimuli[27,28],andlossofEgr1attenuates
the hypertrophic response [29]. The importance of Egr1 in such
a range of systems, together with the emergence of Atf3 as a
negative feedback regulator and the co-regulation of the two
genes in many situations, raises the possibility that the Atf3–
Egr1 negative feedback loop is of broad general signiﬁcance
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Figure 6 ChIP assays for binding of Atf3 to Egr1, Ptgs2 and IL6 promoters
Cardiomyocytes were unstimulated (control) or exposed to ET-1 (100nM for 1 h). Promoter sequences with positions of PCR primers and potential Atf3-binding sites for Egr1 (A), Ptgs2 (C)a n d
IL6 (E) are shown (coding sequence are in bold underlined text; 5  untranslated regions are in underlined italics; positions of primers for PCR are in italic bold; and potential ATF/CRE-binding
sites are shaded and boxed). ChIP was performed using antibodies against Atf3 with sqPCR across the Egr1 (B), Ptgs2 (D)a n dI L 6( F) promoters. Representative images for input DNA and ChIP
DNA are provided (left-hand panels) with densitometric analysis (right-hand panels). Results are means+ −S.E.M. for three myocyte preparations. *P <0.05 relative to control (Student’s t test).
(G) ChIP–PCR was performed for an unrelated sequence approximately 2000bp downstream of the IL6 gene. The experiment was repeated with similar results.
required to restrict expression of Egr1 and maintain a normal
growth response.
Although Atf3 and Egr1 are co-regulated by a range of
stimuli, their up-regulation is usually rapid and transient. As
transcription factors, IEGs such as Atf3 and Egr1 are important in
regulating downstream gene expression, and dysregulation leads
to functional abnormalities and abnormal phenotypic responses.
As demonstrated in the present study (Figure 8), cardiomyocyte
hypertrophy cannot proceed normally in the absence of Atf3.
This is not inconsistent with induction of cardiac hypertrophy in
mice in vivo by overexpression of Atf3 [24]. Atf3 knockout also
enhances cardiac hypertrophy induced by pressure overload in
mice, but, in this model, MAPK signalling (including ERK1/2)
induced by pressure overload is signiﬁcantly enhanced [19]
and this alone could account for enhanced hypertrophy [2,53].
Intriguing questions relate to how Atf3 modulates MAPK
signalling and if the up-regulation of MAPK signalling is
a compensatory mechanism for loss of Atf3. Other studies
indicate that Atf3 is important in regulating, for example, the
immune response [15,17], liver function [54] and pancreatic
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Figure 7 Mathematical modelling of the Atf3–Egr1 feedback system in the cardiomyocyte response to ET-1
(A) Schematic diagram of the system. ET-1 stimulates phosphorylation of MKK1/2 (MKK-P) which phosphorylates and activates ERK1/2 (ERK→ERK-P). Phosphorylated ERK binds to transcription
factors (not shown) on the promoters of Egr1 and Atf3 (Egr1 DNA and Atf3 DNA) to promote transcription and production of Egr1 mRNA and Atf3 mRNA. Atf3 mRNA is translated into Atf3 protein
that eliminates the positive signal from phosphorylated ERK on the Egr1 promoter. ϕ denotes degradation. (B) Results from the mathematical model derived from (A) (see the Supplementary Online
Data at http://www.BiochemJ.org/bj/444/bj4440343add.htm) to show the rates of accumulation of phosphorylated MKK1/2 (upper left-hand panel), phosphorylated ERK (upper right-hand panel),
Egr1 mRNA (centre left-hand panel), Atf3 mRNA (centre right-hand panel), Atf3 protein (lower left-hand panel) and the Atf3 protein–Egr1 DNA complex (lower right-hand panel). The modelling was
performed with (red broken line) or without (blue solid line) feedback regulation of Atf3 on the Egr1 promoter. No attempt was made to switch off either the initial signal from ERK1/2 or production of
Atf3 mRNA.
β-cell function [55,56]. Because of this, it is important to identify
the genes that Atf3 regulates.
At least two previous studies took a systems approach to
identify Atf3-regulated genes, neither of which identiﬁed Egr1
as a target. The ﬁrst focused on TLR4 signalling and the
effects of lipopolysaccharide on the macrophage transcriptome
[15]. The strategy used Cytoscape (software that draws on
published literature to identify protein–protein interactions) to
predictAtf3-regulatedgenesfrommicroarraydataforsubsequent
experimental veriﬁcation. Atf3 was particularly implicated in
negative regulation of IL6. IL6 is up-regulated in cardiomyocytes
by ET-1 as we have reported previously [57] and in the present
study (Figure 4G). We have also previously reported preliminary
data on the effects of AS-Atf3 AdV infection on IL6 mRNA
expression. In those experiments, low viral titres and a low MOI
(<15) were used to suppress the increase in expression of Atf3
by 10 nM ET-1 (rather than 100 nM ET-1 used in the present
study). As in the present study, AS-Atf3 AdVs enhanced the
increase in IL6 mRNA induced by ET-1 [57]. Our interpretation
was that Atf3 suppressed IL6 transcription, consistent with the
report on the role of Atf3 in the TLR4 response [15]. However,
we know now that AdV infection has substantial effects on
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Figure 8 Atf3 is required for cardiomyocyte hypertrophy induced by ET-1
Cardiomyocytes were uninfected (A and B) or were infected with No-AS (C and D) or AS-Atf3 (E–H) AdVs, then unstimulated (Control; A, C, E and G) or exposed to 100nM ET-1 for 24h
(B, D, F and H). Cells were immunostained with antibodies to troponin T. Results are representative of three independent experiments. Scale bar=50μm.
elements of the cardiomyocyte transcriptome and on IL6 in
particular (Figure 2), and the data in the earlier report require re-
interpretation. With submaximal virus and agonist concentrations
(rather than the saturation levels used in the present study), slight
differences between No-AS and AS-Atf3 viral titres were likely
to be exaggerated. The No-AS AdV titre may have been slightly
less than that of the AS-Atf3 AdVs and this could account for
the signiﬁcant effect of AS-Atf3 on IL6 mRNA expression in
control cells over and above that induced by the empty virus. We
assumed that this indicated a basal effect of Atf3 on IL6 mRNA
expression. However, if the effect of AS-Atf3 in control cells is
taken into account, ET-1 stimulation of IL6 mRNA was similar
(∼4-fold) in cardiomyocytes infected with either No-AS or AS-
Atf3 AdVs. We now therefore consider that Atf3 knockdown did
not inﬂuence the increase in expression of IL6 mRNA induced by
ET-1. The lack of an effect of Atf3 knockdown on the increase
in IL6 mRNA expression induced by ET-1 in contrast with the
TLR4 response probably reﬂects a fundamental difference in
the signalling mechanisms. TLR4 signals predominantly through
NF-κB and suppression of IL6 expression by Atf3 results from
its interaction with and inhibition of NF-κB [15]. ET-1 signals
predominantly through ERK1/2 to up-regulate expression of IL6
[5].Withlittle/nosignalthroughNF-κB,Atf3isunlikelytoinhibit
transcriptionofIL6.However,Atf3stillbindstotheIL6 promoter
(Figure6G).ItislessclearwhyEgr1wasnotidentiﬁedasanAtf3-
regulated gene in the TLR4 study [15]. One reason may be that
Cytoscape is informed only by published data. Hence, the study
focused on the Atf3–NFκB interaction and all validations centred
on the NF-κB response.
The second study identifying Atf3-regulated genes focused on
DNA damage in cancer cells. In that study, 5984 potential Atf3-
binding promoters were identiﬁed in HCT116 colon cancer cells
subjected to DNA damage and 1493 were identiﬁed in LNCaP
prostate cancer cells exhibiting enhanced Atf3 expression [19]. In
contrast with TLR4 signalling in macrophages [15], Atf3 plays a
greater role in positive regulation of mRNA expression in these
cancer cells, and there was no obvious effect of Atf3 knockdown
on Egr1 expression. However, this paradigm differs radically
from a growth response associated with IEG expression: Atf3
up-regulation is delayed (mRNA and protein expression are
maximal at 6 and 12 h respectively) and potentially driven by
p53 [58] with many of the Atf3-regulated genes being classic p53
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targets [19]. It should also be considered that cancer cell lines
were used rather than primary cells, and this may inﬂuence the
signalling/gene expression response.
Since Atf3 and Egr1 are co-regulated in many systems, it is
worth considering the extent to which the Atf3–Egr1 feedback
mechanism operates. We expect it will apply in cardiomyocytes
exposed to other stimuli that regulate gene expression primarily
through MAPK signalling. We suggest that the Atf3–Egr1
negative feedback loop operates in other systems that also drive
gene expression primarily through ERK1/2 signalling, but this
awaits further investigation.
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METHODS
Reaction equations
The reaction equations governing the expression of Egr1 and Atf3
mRNA, Atf3 protein and subsequent suppression of Egr1 mRNA
expression by Atf3 protein are described as follows. Each of the
following processes occur at the rate indicated. Further details
on these can be found in Table S1. -P denotes a phosphorylated
version of the protein.
The phosphorylation of MKK by ET-1 is denoted by:
ET-1 + MKK
k1
→ ET-1 + MKK-P (1)
which subsequently phosphorylates the unphosphorylated ERK:
MKK-P + ERK
k2
→ MKK-P + ERK-P (2)
ERK-P is now free to transcribe both Egr1 and Atf3 mRNA such
that:
ERK-P + DNAEgr1
k3

k−3 ERK-P · DNAEgr1
k4
→ mRNAEgr1 (3)
and:
ERK-P + DNAAtf3
k5

k−5 ERK-P · DNAAtf3
k6
→ mRNAAtf3 (4)
which are both degraded:
mRNAEgr1
d1
→ φ, mRNAAtf3
d2
→ φ (5)
Here · denotes a complex and φ the degraded mRNA.
The suppression of Egr1 mRNA transcription by Atf3 is
described by:
ERK-P · DNAEgr1 + Atf3
k7
→ Atf3 · DNAEgr1 (6)
where the concentration of ERK-P is considered to be in excess.
Finally the translation of Atf3 mRNA to Atf3 protein and
subsequent degradation of the protein are denoted by:
mRNAAtf3
k8
→ Atf3 and Atf3
d3
→ φP (7)
respectively, where φP denotes degraded protein. In the present
study we do not explicitly account for the degraded mRNAs or
Atf3 protein.
Mathematical model
The Law of Mass Action [6] was applied to eqns (1)–(7). This
led to the following system of nonlinear ordinary differential
equations:
dm
dt
=− k1etm (8)
dmP
dt
= k1etm (9)
dE
dt
=− k2mPE (10)
dEP
dt
= k2mPE − k3EPDE + k−3TE − k5EPDA + k−5TA (11)
dDE
dt
=− k3EPDE + k−3TE (12)
dTE
dt
= k3EPDE − k−3TE − k7TE A (13)
dME
dt
= k4TE − d1ME (14)
dDA
dt
=− k5EPDA + k−5TA (15)
dTA
dt
= k5EPDA − k−5TA (16)
dMA
dt
= k6TA − d2MA (17)
dA
dt
= k8MA − k7TE A − d3A (18)
dS
dt
= k7TE A (19)
Each of the variables is deﬁned as follows: eT represents
the concentration of ET-1 (denoted eT =[ET-1]), m=[MKK],
mP =[MKK-P], E=[ERK], EP =[ERK-P], DE =[DNAEgr1],
DA =[DNAAtf3], TE =ERK-P·DNAEgr1, TA =ERK-P·DNAAtf3,
ME =[mRNAEgr1], MA =[mRNAAtf3], S=[Atf3·DNAEgr1]a n d
1 These authors contributed equally to this work.
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A=[Atf3]. In the present study the concentration of ET-1 is
assumed to be constant. The rate of Atf3 protein to Egr1 DNA
binding is assumed to be immediate and no delays are incurred in
this process.
The system is closed with the initial conditions:
m = m0, mP = 0, E = E0, EP = 0, DE = DE0, TE = 0,
ME = ME0, DA = DA0, TA = 0, MA = 0, A = 0a n d
S = 0 (20)
which state that MKK and ERK are initially assumed to be
unphosphorylated, the concentration of Egr1 mRNA is non-zero
whereas no Atf3 mRNA, Atf3 protein or any of the complexes
have been created.
Thegoverningsystemofequationscanbesimpliﬁedasfollows.
Addition of eqns (8) and (9), integration with respect to time
and application of the respective initial conditions yields the
conservation relation:
m + mP = m0 (21)
Substitutingformintoeqn(9),integratingandapplyingtheinitial
condition yields:
mP(t) = m0

1 − e
−k1eT t
(22)
Addition of eqns (12), (13) and (19), integration with respect
to t and application of the initial conditions yields.
DE + TE + S = DE0 (23)
Likewise for eqns (15) and (16):
DA + TA = DA0 (24)
Assuming eqn (16) is quasi-steady and substituting for DA using
eqn (24) leads to:
TA  
DA0EP
EP + K5
(25)
where K5 = k−5/k5.
Bringing all these results together gives:
mP(t) = m0

1 − e
−k1eT t
(26)
dE
dt
=− k2mPE (27)
dEP
dt
= k2mPE − k3EP(DE0 − TE − S) + k−3TE (28)
dTE
dt
= k3EP(DE0 − TE − S) − k−3TE − k7TE A (29)
dME
dt
= k4TE − d1ME (30)
dMA
dt
=
k
∗
6EP
EP + K5
− d2MA (31)
dA
dt
= k8MA − k7TE A − d3A (32)
dS
dt
= k7TE A (33)
with the initial conditions:
E = E0, EP = 0, TE = 0, ME = ME0, MA = 0,
A = 0a n dS = 0 (34)
where k
∗
6 = k6DA0. When Egr1 transcription is not suppressed by
Atf3 protein we have k7 = 0.
Parameterization
The mathematical model has been informed with data available
within the literature, from our own previous studies as well the
present study. A complete list of the parameter values used can
be found in Table S1. In cases where parameter values have been
derived these are explained as follows.
Estimation of the activation rate of MKK and ERK
The time course for activation of ERK1 was determined
previously [9] and maximal activation was at 3 min. The time
courseforactivationofMKKwasdeterminedbyimmunoblotting
with antibodies against phosphorylated (i.e. activated) MKK
(Cell Signaling Technology). A representative blot is shown in
Figure S1. The time course for activation by a range of agonists
(epidermal growth factor, ET-1, phorbol 12-myristate 13-acetate
or platelet-derived growth factor) all showed maximal activation
by 2–3 min. We therefore assumed the time to maximal activation
of MKK to be 2 min with a further 1 min for maximal activation
of ERK.
The concentration of MKK in cardiomyocytes was estimated
by immunoblotting cardiomyocyte extracts from a known
number of cells alongside known concentrations of recombinant
MKK1. Antibodies against total MKK were from Cell Signaling
Technology. Following densitometric analysis, a standard curve
was constructed from which the amount of MKK in the myocyte
extract was estimated. The concentration was calculated on
the basis of the estimated volume of a neonatal myocyte. The
concentration of ERK was assumed to be similar to MKK given
that this lies within the range seen in other cells [4].
k1et: Rate of MKK activation by ET-1
The time taken for maximal activation of MKK by ET-1 is 2 min,
thus:
k1et =
1
120 s
= 8.30 × 10
−3 s
−1
k2: Rate of ERK activation by MKK
The time taken to activate ERK by MKK is 60 s, so:
k2E =
1
60 s
= 1.67 × 10
−2 s
−1
The total ERK concentration is 130 nM such that:
k2 = 1.28 × 10
5 (Ms)
−1
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Figure S1 Activation of MKK phosphorylation by ET-1 (A) and effect of
actinomycin D on Egr1 and Atf3 transcription (B)
(A) Cardiomyocytes were exposed to ET-1 for the times indicated. Protein extracts were
immunoblotted with antibodies to phospho-MKK. A representative image is shown. (B)
Cardiomyocytes were stimulated for 30min before addition of actinomycin D (4μM) to inhibit
transcription. Expression of Egr1 (upper panel) or Atf3 (lower panel) mRNAs were measured by
qPCR at the indicated times after actinomycin D addition. A one-phase exponential curve was
ﬁtted using GraphPad Prism 4.
k∗
4, k∗
6: Egr1 and Atf3 transcription rates
The size of the Atf3 and Egr1 genes, mRNAs and proteins were
for mouse (for rat, the 5
  untranslated region was not deﬁned for
Egr1 and the rat genome is not well sequenced in the intronic
regions for Atf3). Sequences were obtained from the NCBI. For
Atf3(GeneID:11910),thisgivesatotalgenelengthof13038base
pairs (bp), a 5
  untranslated region of 62 nucleotides and protein
of 181 amino acids. For Egr1 (Gene ID: 13653), this gives a total
gene length of 3750 bp. To estimate the rate of transcription, the
total length of the gene was used allowing for an additional 200
nucleotides to be transcribed before termination. The maximum
rate of transcription has been estimated recently to range from 55
bases/s to greater than 800 bases/s [1,5]. Thus to transcribe one
molecule of mRNA from one gene, assuming a rate of 55 bases/s,
takes:
3950 bases
55 bases/s
= 71.82 s
Pergene,thisequatesto1.39 × 10
−2 molecules mRNA s
−1.Since
a cell contains two genes, we have 2.78 × 10
−2 molecules of Egr1
mRNA being synthesized per cell per s. Taking the cell volume
of 6.7 pl we obtain:
k
∗
4 =
2.78 × 10
−2 molecules · s
−1
6.7 × 10−9 ml
= 4.15 × 10
5 molecules·ml
−1 ·s
−1=6.89 × 10
−16 Ms
−1 (35)
We can undertake a similar calculation for Atf3 transcription to
obtain:
k
∗
6 = 5.15 × 10
−15 Ms
−1
k8: Atf3 translation rate
The rate of translation of Atf3 was estimated on the basis of
scanning of the 5
  untranslated region at a rate of six nucleotides/s
[11], translation of the coding sequence at a rate of 20 amino
acids/s (N.B. the reported rate of translation is in the range of
4–20 amino acids/s [10,12] and we presume translation of IEGs
is efﬁcient) with ﬁve ribosomes attached simultaneously to each
mRNA (N.B. the predicted occupancy is one ribosome per 32
amino acids) [7].
K5 and k3, k−3: ERK-P dissociation rates for Egr1 and Atf3 DNA
The model is based on the assumption that phospho-ERK bind
to transcription factors that are pre-bound to the Atf3 and Egr1
promoters and this drives transcription. We presume that the ERK
binding is mediated through a DEF motif with an estimated
dissociation rate of 0.5 μM (the dissociation rate for Elk1 is
0.25 μM; that for Fos is 1 μM) [2]. Given that K3 = k−3/k3,w e
use an initial estimate of k−3 = 5 × 10
−2/s to obtain k3 = 1 × 10
5
(Ms)
−1.
d1, d2, d3: Degradation rates of Egr1 mRNA, Atf3 mRNA and Atf3 protein
Toestimatethehalf-lifeofEgr1andAtf3mRNA,cardiomyocytes
were exposed to ET-1 for 30 min then incubated without or
with actinomycin D (4 μM, added directly to the culture dish).
Cells were harvested at the indicated times following addition of
actinomycin D and mRNA expression was measured by qPCR.
GraphPad Prism 4 was used to ﬁt a one-phase exponential decay
curve to the data shown in Figure S1, giving a half-life of 13 min
for Egr1 and 49 min for Atf3. The rate of degradation is deﬁned
by:
d =
ln2
t1/2
which leads to:
d1 = 8.89 × 10
−4 s
−1 and d2 =
ln2
2580 s
= 2.36 × 10
−4s
−1 (36)
We assume Atf3 protein degrades at the same rate as Atf3 mRNA.
Egr1 DNA concentration
We assume there are two molecules of DNA per cell. The volume
of a neonatal myocyte was estimated given that an adult myocyte
has a volume of 34 pl with a capacitance of 66 pF [3,8] and the
capacitance of a neonatal myocyte is 13 pF [8]. This gives 6.7 pl
per cell leading to concentration of 33.2 pM.
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Table S1 Model parameter values
Parameter Deﬁnition Value
m0 Total MKK 130nM
E0 Total ERK 130nM
ME0 Initial Egr1 mRNA concentration 1pM
De0 Egr1 DNA concentration 33.2pM
k1et Rate of MKK activation by ET-1 8.30×10−3 s−1
k2 Rate of ERK activation by MKK 1.28×105(Ms)−1
k3 Rate of ERK-P activation of Egr1 DNA 1.00×105(Ms)−1
k−3 Rate of ERK-P reverse activation 5.00×10−2(Ms)−1
of Egr1 DNA
k∗
4 Egr1 mRNA transcription rate 6.89 ×10−15 M/s
k∗
6 Atf3 mRNA transcription rate 1.03 ×10−15 M/s
k7 Atf3 supression rate To be determined
k8 Atf3 translation rate 0.25 s−1
K5 ERK-P and Atf3 DNA dissociation rate 0.5×10−6 M
d1 Degradation rate of Atf3 mRNA 8.89 ×10−4 s−1
d2 Degradation rate of Egr1 mRNA 2.36 ×10−4 s−1
d3 Degradation rate of Atf3 protein 2.36 ×10−4 s−1
RESULTS
Thegoverningsystemofnonlinearordinarydifferentialequations
(ODEs) (eqns 27–33) was solved using Gear’s method available
in Matlab (The Mathworks, Version 7.11) via the solver ode15,
with mP(t) given by eqn (26).
Using the parameter values detailed in Table S1 we found the
20-fold change in Egr1 mRNA determined experimentally could
not be reproduced using these values [using an initial estimate of
k7 = 1 × 10
5 (Ms)
−1]. As such we undertook a sensitivity analysis
inwhichwevariedtheratesofEgr1andAtf3mRNAtranscription
(k
∗
4,k
∗
6), ERK-P reverse activation of Egr1 DNA (k−3)a n dt h e
ERK-P association rate for Atf3 DNA (K3). The most appropriate
variation in these values which gave a good ﬁt to the data was
foundtobea5-foldincreaseinboththetranscriptionratesofEgr1
and Atf3 mRNA (5 × k
∗
4,5 × k
∗
6), a 10-fold decrease in the rate of
ERK-PdissociationforEgr1DNA(k−3/10)anda50-folddecrease
in the ERK-P association rate for Atf3 DNA (K3/50). Such a
variation in the rates of Egr1 and Atf3 transcription is equivalent
to a rate of 275 bases/s rather than the original assumption of 55
bases/s. Such a variation lies within the range recently reported
in [1] and [5].
This led to a very good ﬁt to the experimental data in terms of
the magnitude variation in Egr1 mRNA observed experimentally
and a relatively good ﬁt (qualitatively) to the supression of Egr1
mRNAbyAtf3.Tofurtherimprovethismodel-dataﬁtweadjusted
the rate of Atf3 suppression (k7). Good ﬁts to the data were
obtained for the range of values 1.00 × 10
5 (Ms)
−1  k7  6 ×
10
5 (Ms)
−1.
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Table S2 Primers used for qPCR and sqPCR
mRNA sequences were from the Rat Genome Database (http://www.ncbi.nlm.nih.gov/entrez).
Gene symbol (GenBank® accession number) Size (bp) Forward primer (position in sequence) Reverse primer (position in sequence)
(a) qPCR primers
Atf3 (NM_012912.1) 108 5 -TCGCCATCCAGAACAAGCA-3  (140–158) 5 -GGGCCACCTCAGACTTGGT-3  (229–247)
Egr1 (NM_012551.2) 98 5 -CTACGAGCACCTGACCACAGAGTC-3  (204–227) 5 -GCAACCGGGTAGTTTGGCT-3  (283–301)
Gapdh (NM_017008.3) 93 5 -CCAAGGTCATCCATGACAACTT-3  (476–497) 5 -AGGGGCCATCCACAGTCTT-3  (550–568)
Ptgs2 (NM_017232.3) 90 5 -GAAGAACTTACAGGAGAGAAAGAAATGG-3  (1393–1420) 5 -CAGCAGGGCGGGATACAGT-3  (1464–1482)
Dusp1 (NM_053769.3) 62 5 -GCGCGCTCCACTCAAGTC-3  (337–354) 5 -GGGCAGGAAGCCGAAAAC-3  (381–398)
Dusp5 (NM_133578.1) 70 5 -CGACATTAGCTCCCACTTTCAA-3  (882–903) 5 -AGGACCTTGCCTCCCTCTTC-3  (934–953)
Areg (NM_017123.1) 108 5 -CTGCTGGTCTTAGGCTCAGG-3  (218–237) 5 -CACAAGTCCACCAGCACTGT-3  (306–325)
Il6 (NM_012589.1) 157 5 -GAGTTGTGCAATGGCAATTC-3  (202–221) 5 -ACTCCAGAAGACCAGAGCAG-3  (339–358)
Il1rl1 (NM_013037.1) 100 5 -GCCCTTCATCTGGGCTACACT-3  (68–88) 5 -GCAATGGCACAGGAAGGTAAC-3  (147–167)
(b) sqPCR primers
Atf3 (NM_012912.1) 331 5 -GCTGCCAAGTGTCGAAACAAG-3  (298–318) 5 -CAGTTTTCCAATGGCTTCAGG-3  (608–628)
Gapdh (NM_017008.3) 452 5 -ACCACAGTCCATGCCATCAC-3  (520–539) 5 -TCCACCACCCTGTTGCTGTA-3  (952–971)
Table S3 Response of cardiomyocyte transcriptome to adenoviral infection
Cardiomyocytes were uninfected (no virus) or infected with empty AdVs and gene expression proﬁles were examined using Affymetrix microarrays. The data were analysed using GeneSpring to
identify transcripts that were signiﬁcantly changed (>1.5-fold, FDR < 0.05) by AdV infection. Transcripts are clustered according to known or probable function and are listed alphabetically with
up-regulated transcripts listed ﬁrst. Results are means for n=3 independent hybridizations each representing three separate preparations of cardiomyocytes.
Probeset Gene symbol Gene description Raw values (no virus) Fold change induced by virus
(a) Antiviral response
7196285 Adar Adenosine deaminase, RNA-speciﬁc 204 1.80*
7315869 Ddit3 DNA-damage inducible transcript 3 273 2.27*
7301235 Iﬁ27 Interferon α-inducible protein 27 1785 1.98*
7072322 Iﬁ35 Interferon-induced protein 35 91 1.97*
7215722 Iﬁ44 Interferon-induced protein 44 126 3.96*
7067089 Iﬁ47 Interferon-inducible protein 47 141 7.07*
7041465 Iﬁt2 Interferon-induced protein with tetratricopeptide repeats 2 89 1.89*
7041467 Iﬁt3 Interferon-induced protein with tetratricopeptide repeats 3 57 3.38*
7170909 Iigp1 Interferon inducible GTPase 1 106 4.47*
7067595 Irf1 Interferon regulatory factor 1 154 1.72*
7131960 Irf9 Interferon regulatory factor 9 443 2.28*
7092176 Mx1|2 Myxovirus (inﬂuenza virus) resistance 1/2 55 19.37*
7087207 Mx2|1 Myxovirus (inﬂuenza virus) resistance 2/1 122 19.05*
7098547 Oas1a/k 2 -5  Oligoadenylate synthetase 1A/K 91 12.05*
7102451 Oas1b/i 2 -5  Oligoadenylate synthetase 1B/I 55 6.03*
7098544 Oas1i 2 -5  Oligoadenylate synthetase 1I 73 5.81*
7102456 Oas1k/a 2 -5  Oligoadenylate synthetase 1K/A 97 1.80*
7103432 Oas2 2 -5  Oligoadenylate synthetase 2 41 3.58*
7102992 Oasl 2 -5  Oligoadenylate synthetase-like 101 11.64*
7103001 Oasl2 2 -5  Oligoadenylate synthetase-like 2 84 9.95*
7339147 Plscr1 Phospholipid scramblase 1 104 1.69*
7305174 Rsad2 Radical S-adenosylmethionine domain-containing 2 61 12.13*
7055354 Trim5 Tripartite motif-containing 5 835 1.52
7263822 Zc3hav1 Zinc ﬁnger CCCH type, antiviral 1 124 2.05
(b) Cytokine/chemokine signalling
7073869 C1qtnf1 C1q and tumour necrosis factor-related protein 1 189 1.58
7356847 Ccl20 Chemokine (C-C motif) ligand 20 146 1.77
7070340 Ccl7 Chemokine (C-C motif) ligand 7 1918 2.00
7212626 Csf1 Colony-stimulating factor 1 (macrophage) 122 1.84
7071906 Csf3 Colony-stimulating factor 3 (granulocyte) 220 2.80
7116933 Cxcl10 Chemokine (C-X-C motif) ligand 10 37 5.21
7116931 Cxcl11 Chemokine (C-X-C motif) ligand 11 472 1.81
7123570 Cxcl13 Chemokine (C-X-C motif) ligand 13 132 1.69
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Table S3 Continued
Probeset Gene symbol Gene description Raw values (no virus) Fold change induced by virus
7055111 Il18bp IL18-binding protein 155 1.92
7260080 Il6 IL6 149 5.13
7138335 Ripk3 Receptor-interacting serine-threonine kinase 3 151 1.71
7362008 Stat1/4 Signal transducer and activator of transcription 1/4 906 2.26
7311784 Stat2 Signal transducer and activator of transcription 2 157 3.36
7216733 Tnf Tumour necrosis factor (TNF superfamily, member 2) 94 2.19
7327525 Tnfrsf11b Tumour necrosis factor receptor superfamily, member 11b 1001 1.93
7098502 Trafd1 TRAF (tumour-necrosis-factor-receptor-associated factor) type zinc ﬁnger domain
containing 1
192 1.50
7351276 Ccr1 Chemokine (C-C motif) receptor 1 123 0.53
7041124 Il33 IL33 100 0.64
7123902 Pf4 Platelet factor 4 704 0.59
(c) Immune/inﬂammatory response
7149693 Bst2 Bone marrow stromal cell antigen 2 165 3.21*
7093567 Cd80 CD80 molecule 80 2.20
7093779 Cd86 CD86 molecule 106 1.63
7216827 Cfb Complement factor B 66 2.85
7296860 Cmpk2 Cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial 72 7.20*
7327552 Enpp2 Ectonucleotide pyrophosphatase/phosphodiesterase 2 127 2.31
7107717 Fcgr3a Fc fragment of IgG, low afﬁnity IIIa, receptor 160 2.86
7200128 Gbp2 Guanylate-binding protein 2 101 7.94*
7076940 Irgm Immunity-related GTPase family, M 240 6.43
7293880 Isg15 ISG15 ubiquitin-like modiﬁer 64 14.88*
7033289 Isg20 Interferon-stimulated exonuclease gene 20 84 2.56*
7270067 Klrk1 Killer cell lectin-like receptor subfamily K, member 1 28 1.72
7084895 Lgals3bp Lectin, galactoside-binding, soluble, 3 binding protein 319 3.79*
7080131 Lgals5/9 Lectin, galactose-binding, soluble 5/9 116 2.19*
7080134 Lgals9/5 Lectin, galactoside-binding, soluble, 9/5 162 4.47*
7069999 Nos2 Nitric oxide synthase 2, inducible 65 1.87
7266324 Reg3g Regenerating islet-derived 3γ 1758 1.57
7216994 RT1 class Ia, locus A2/A1 | locus A3 | RT1 class Ib, locus EC2 | MHC class I RT1.Aa
alpha-chain
289 2.02
7220575 RT1 class I, locus1 | RT1 class I, locus CE12/CE14 271 2.24
7216676 RT1 class I, locus CE10/CE7/CE11 164 1.72
7224452 RT1 class I, locus CE11/CE7 | RT1 class Ib, locus EC2 271 2.00
7224458 RT1 class I, locus CE12/14 | RT1 class I, locus1 244 2.31
7224429 RT1 class I, locus CE13/CE14 102 1.78
7224511 RT1 class I, locus CE15 422 1.76
7220557 RT1 class I, locus CE3/A3 | RT1 class Ia, locus A1/A2 | RT1 class Ib, locus EC2 116 1.75
7220541 RT1 class I, locus CE5/CE4 | RT1 class Ib, locus EC2 | 327 2.04
MHC class I RT1.Aa alpha-chain | mature alpha chain of MHC class Ib protein-like
7216505 RT1 class Ib, locus N2/N1/N3 103 1.66
7216519 RT1 class Ib, locus N3/N1/N2 189 2.17
7216562 RT1 class I, locus T24, gene 1/4 | MHC class I 198 2.09
RT1.O type 149 processed pseudogene
7216540 RT1 class I, locus T24, gene 1/1/4 | MHC class I | RT1.O type 149 processed
pseudogene | RT1 class Ib, locus EC2
210 3.82
7220923 Tap1 Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 120 3.12
7220903 Tap2 Transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) 106 1.77
7221026 Tapbp TAP-binding protein 239 2.78
7269637 Tapbpl/Vamp1 TAP-binding proteinlike | vesicle-associated membrane protein 1 113 1.59
7145662 Tlr3 Toll-like receptor 3 80 1.83
7226106 Tor1b Torsin family 1, member B 154 1.51*
7112701 Tor3a Torsin family 3, member A 162 1.91*
7071036 Trim25 Tripartite motif-containing 25 194 2.01*
7295338 Xdh Xanthine dehydrogenase 155 1.56*
7226238 Aif1l| Lamc3 Allograft inﬂammatory factor 1-like | laminin γ3 920 0.65*
7111837 Cfh Complement factor H 122 0.60
7325371 Lyz2| Lyc2 Lysozyme 2 | lysozyme C type 2 350 0.59
7321134 Mir196a MicroRNA mir-196a 72 0.66*
(d) Agonists/receptors
7035427 Adm Adrenomedullin 210 1.52
7322881 Angptl4 Angiopoietin-like 4 186 1.74
7301401 Bdkrb1 Bradykinin receptor B1 53 1.81*
7232862 Bmp2 Bone morphogenetic protein 2 40 1.97
7123853 Ereg Epiregulin 55 2.55
7204090 Fst Follistatin 83 1.93
7144218 Gdf15 Growth differentiation factor 15 168 2.89
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Table S3 Continued
Probeset Gene symbol Gene description Raw values (no virus) Fold change induced by virus
7261075 Hgf Hepatocyte growth factor 155 1.57
7348035 Htr1b 5-hydroxytryptamine (serotonin) receptor 1B 33 1.60
7318105 Ly6e Lymphocyte antigen 6 complex, locus E 127 2.89
7216279 Olr1730 Olfactory receptor 1730 42 1.64
7201157 Ptger3 Prostaglandin E receptor 3 (subtype EP3) 64 1.59
7055094 Folr2 Folate receptor 2 (fetal) 174 0.66
7364798 Htr2b 5-hydroxytryptamine (serotonin) receptor 2B 99 0.65
7313468 Igf1 Insulin-like growth factor 1 2690 0.36
7071991 Igfbp4 Insulin-like growth factor binding protein 4 494 0.63
7146031 Msr1 Macrophage scavenger receptor 1 640 0.57
7055209 Olr63 Olfactory receptor 63 180 0.61
7263730 Ptn Pleiotrophin 825 0.37
7094158 Tfrc Transferrin receptor 1300 0.58
(e) Cell adhesion/extracellular matrix
7296103 Sdc1 Syndecan 1 184 1.78
7247754 Sdc4 Syndecan 4 1059 1.57
7213140 Vcam1 Vascular cell adhesion molecule 1140 1.78
7202072 Vcan Versican 618 1.62
7317088 Col14a1 Collagen, type XIV, α1 271 0.64
7319496 Fbln1 Fibulin 1 299 0.65
7260805 Fgl2 Fibrinogen-like 2 254 0.60
7169581 Pcdhb21 Protocadherin β21 88 0.65
(f) Cell cycle/cell death
7341999 Birc3 Baculoviral IAP repeat-containing 3 70 1.55
7321430 Cdk2 Cyclin-dependent kinase 2 229 1.57
7217282 Cdkn1a Cyclin-dependent kinase inhibitor 1A 1072 2.49
7114725 Ephx1 Epoxide hydrolase 1, microsomal 124 2.25
7041442 Fas Fas (tumour necrosis receptor superfamily member 6) 275 1.62
7055435 Hpx Haemopexin 93 2.43
7325416 Mdm2 Mdm2 p53-binding protein homologue (mouse) 678 1.64
7211447 Mllt11 Myeloid/lymphoid or mixed-lineage leukaemia 121 1.62
(trithorax homologue, Drosophila); translocated to, 11
7192589 Tnfsf10 Tumour necrosis factor (ligand) superfamily, member 10 53 2.00
7207681 Ccna2 Cyclin A2 261 0.56
7203074 Ccnb1 Cyclin B1 354 0.66
7218195 Cdc2 Cell division cycle 2, G1 to S and G2 to M 234 0.55
7132836 Pbk PDZ-binding kinase 164 0.57
7338657 Ttk Ttk protein kinase 88 0.64
(g) Protein synthesis/modiﬁcation/folding/degradation
7088621 Dtx3l Deltex 3-like (Drosophila)5 5 2 . 1 6
7114108 Eef1g|Slamf7 Eukaryotic translation elongation factor 1γ SLAM family member 7 302 1.56
7260038 Mettl20 Methyltransferase like 20 114 1.52
7361254 Mitd1 MIT, microtubule interacting and transport, domain containing 1236 2.46
7220914 Psmb8 Proteasome (prosome, macropain) subunit, β type 8 (large multifunctional peptidase 7) 62 1.76
7216935 Psmb9 Proteasome (prosome, macropain) subunit, β type 9 (large multifunctional peptidase 2) 170 3.44
7138231 Psme2 Proteasome (prosome, macropain) activator subunit 2 1159 1.61
7103916 Serpinb2 Serine (or cysteine) peptidase inhibitor, clade B, member 2 180 7.32
7101220 Serpine1 Serine (or cysteine) peptidase inhibitor, clade E, member 1 214 1.98*
7241130 Serping1 Serine (or cysteine) peptidase inhibitor, clade G, member 1 597 1.55*
7195163 Serpini1 Serine (or cysteine) peptidase inhibitor, clade I, member 1 113 2.12
7247744 Slpi|Slpil2 Secretory leucocyte peptidase inhibitor|antileukoproteinase-like 2 1043 2.21
7374050 Capn6 Calpain 6 107 0.57
7332657 Mmp12 Matrix metallopeptidase 12 1365 0.44
(h) Regulation of metabolism/signalling/transcription
7250403 Abcb1b/1a ATP-binding cassette, sub-family B (MDR/TAP),member 1B/1A 175 3.24
7318515 Apol3 Apolipoprotein L, 3 168 1.53
7226167 Ass1 Argininosuccinate synthetase 1 216 1.85
7356120 Cyp27a1 Cytochrome P450, family 27, subfamily a, polypeptide 1 218 1.90
7352252 Enpp4 Ectonucleotide pyrophosphatase/phosphodiesterase 4 243 1.72
7363922 Glb1l Galactosidase, β1-like 150 1.54
7327675 Has2 Hyaluronan synthase 2 256 1.78
7037881 Mgmt O-6-methylguanine-DNA methyltransferase 158 1.54
7185182 Nqo1 NAD(P)H dehydrogenase, quinone 1 241 1.52
7093806 Parp9 Poly (ADP-ribose) polymerase family, member 9 80 1.81
7329573 Pvalb Parvalbumin 57 1.56
7237508 Ptges Prostaglandin E synthase 252 3.02
7106132 Ptgs2 Prostaglandin-endoperoxide synthase 2 136 1.92
7339559 Rbp2 Retinol-binding protein 2, cellular 93 2.28
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Table S3 Continued
Probeset Gene symbol Gene description Raw values (no virus) Fold change induced by virus
7041029 Rcl1 RNA terminal phosphate cyclase-like 1 391 1.57
7244077 Slc28a2 Solute carrier family 28 (sodium-coupled nucleoside transporter), member 2 174 1.57
7250503 Steap1 Six transmembrane epithelial antigen of the prostate 1 419 1.81
7184185 Asf1b ASF1 anti-silencing function 1 homologue B (S. cerevisiae) 176 0.65
7115455 Atf3 Activating transcription factor 3 183 0.45
7197511 Casq2 Calsequestrin 2 (cardiac muscle) 1048 0.58
7156835 F13a1 Coagulation factor XIII, A1 polypeptide 237 0.34
7250763 Gng11 Guanine nucleotide-binding protein (G protein), gamma 11 826 0.65
7164749 Hist1h2ail Histone cluster 1, H2ai-like 1978 0.62
7034549 Kcne3 Potassium voltage-gated channel, Isk-related subfamily, gene 3 548 0.61
7240783 Pde1a Phosphodiesterase 1A, calmodulin-dependent 343 0.61
7261911 Pdk4 Pyruvate dehydrogenase kinase, isozyme 4 219 0.66
7288397 Ptplad2 Protein tyrosine phosphatase-like A domain containing 2 141 0.66
7362066 Sdpr Serum deprivation response 835 0.56
7219202 Smpdl3a Sphingomyelin phosphodiesterase, acid-like 3A 618 0.65
7025936 Tcf21 Transcription factor 21 724 0.63
(i) Proteins with no known function/hypothetical proteins
7329479 Apol9a Apolipoprotein L 9a 147 4.07
7220127 Ascc3 Activating signal cointegrator 1 complex subunit 3 215 1.77
7070512 LOC360228 WDNM1 homologue 139 1.57
7333434 LOC500956 Unknown 150 1.53
7138718 Phf11/11l PHD ﬁnger protein 11/11-like 46 2.81
7260055 RGD1309621 Similar to hypothetical protein FLJ10652 155 2.46
7065377 RGD1561157 Unknown 117 1.71
7235527 Rnf114 Ring ﬁnger protein 114 951 1.70*
7073915 Rnf213 Ring ﬁnger protein 213 51 2.54
7073928 Rnf213 Ring ﬁnger protein 213 65 1.99
7094771 Rtp4|Ctdsp1 Receptor (chemosensory) transporter protein 4 | CTD (carboxy-terminal domain, RNA
polymerase II, polypeptide A) small phosphatase 1
139 11.46*
7070419 Slfn3 Schlafen 3 131 5.04*
7070393 Slfn5 Schlafen family member 5 98 1.85*
7072336 Tmem106a Transmembrane protein 106A 78 1.85
7252491 Tmem140 Transmembrane protein 140 206 1.83
7047575 Unknown Unknown 55 1.57
7088625 Unknown Unknown 88 2.72
7116103 Unknown Unknown 71 2.16
7129836 Unknown Unknown 38 1.54
7153410 Unknown Unknown 96 1.74
7254427 Unknown Unknown 119 1.55
7328454 Unknown Unknown 46 1.64
7371101 Unknown Unknown 54 2.67
7126637 Cd38 CD38 molecule 608 0.61
7191192 Fam134b Family with sequence similarity 134, member B 1202 0.62
7372873 Fam70a Family with sequence similarity 70, member A 534 0.51
7133474 Lcp1 Lymphocyte cytosolic protein 1 545 0.57
7164764 LOC680097 Similar to germinal histone H4 gene 6612 0.58
7367891 LOC680166 Unknown 204 0.61
7157871 LOC682649 Similar to Histone H2A type 1 647 0.53
7260779 Lrrc17 Leucine rich repeat containing 17 298 0.38
7060488 Ms4a6b/11 Membrane-spanning 4-domains, subfamily A, member 6B/11 215 0.52
7337370 Ns5atp9 NS5A (hepatitis C virus) transactivated protein 9 307 0.66
7035206 Olfml1 Olfactomedin-like 1 355 0.48
7328472 Tmem71 Transmembrane protein 71 128 0.59
7077262 Unknown Unknown 100 0.66
7135004 Unknown Unknown 194 0.62
7164849 Unknown Unknown 845 0.66
7176278 Unknown Unknown 208 0.65
7367340 Unknown Unknown 67 0.57
7368283 Unknown Unknown 409 0.63
7369003 Unknown Unknown 1284 0.63
7370879 Unknown Unknown 86 0.63
*Transcripts identiﬁed as part of an interferon response in other systems.
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Table S4 Transcripts up-regulated by ET-1 that are regulated by Atf3, but are unaffected by No-AS virus infection
*IEG; **non-IEG.
Control ET-1
Transcript cluster Gene symbol Raw values No virus No-AS AS-Atf3 No virus No-AS AS-Atf3
(a) AS Atf3 enhances response to ET-1
Cluster A1
7169197 Egr1* 289 1 0.95 1.02 1.29 1.24 4.73
7222466 Egr2* 85 1 0.92 0.87 1.32 1.59 2.90
7288744 Jun* 425 1 0.93 1.44 1.21 1.31 2.10
7320920 Nr4a1* 64 1 0.95 1.12 3.78 4.29 6.63
Cluster A2
7308330 Actn1* 152 1 0.94 2.61 2.72 2.22 3.56
7185572 Bcar1* 154 1 1.05 1.94 1.56 1.41 2.23
7231595 Chac1** 142 1 1.01 2.04 0.96 1.08 3.03
7114850 Enah* 130 1 0.98 2.28 2.00 1.60 2.86
7265600 Gadd45a** 854 1 1.00 2.94 1.98 1.93 3.09
7243216 Grem1** 52 1 1.13 1.81 1.83 1.49 2.68
7179800 Ier2* 368 1 0.96 2.16 1.67 1.79 4.56
7354973 Nop58 195 1 0.95 2.86 1.93 1.62 3.39
7124933 Rasl11b* 500 1 1.13 2.22 1.73 1.91 3.02
7096358 Slc7a1** 88 1 1.10 2.80 2.18 1.74 3.54
7115195 Tgfb2** 181 1 1.06 2.77 1.79 1.67 2.99
(b) AS Atf3 inhibits response to ET-1
Cluster B1
7260283 Insig1 2796 1 0.94 0.62 1.54 1.50 0.95
7144691 Sc4mol** 1376 1 0.99 0.60 1.72 1.72 0.89
7133039 Stc1* 560 1 1.17 0.58 1.21 1.23 0.59
Cluster B2
7123129 Agpat9 65 1 0.96 1.07 2.82 2.22 1.40
7123848 Areg** 127 1 1.07 1.20 5.63 7.01 2.09
7043230 Dusp5** 178 1 0.93 0.87 3.03 2.99 1.54
7345585 Fdx1** 459 1 0.87 0.93 2.94 3.05 1.98
7187674 Glrx1 191 1 0.94 0.82 1.66 1.92 1.14
7202670 Hmgcr* 527 1 1.00 0.72 1.62 1.71 1.04
7150663 Mfap3l 116 1 0.98 0.91 1.66 1.34 0.88
7235566 Pard6b** 62 1 1.06 1.19 3.20 3.62 1.48
7204067 Pelo** 863 1 1.12 1.19 1.76 1.90 1.24
7104906 RGD1562617 127 1 0.90 0.88 2.36 1.41 0.89
7214260 Sgms2 77 1 1.03 1.04 4.42 3.27 1.28
7141508 Spry2** 513 1 0.99 1.20 2.87 2.79 1.74
7297329 Twist1** 126 1 1.14 0.96 2.83 3.77 2.24
7350922 Xirp1** 217 1 1.02 1.40 4.09 3.53 1.70
7297247 Unknown 121 1 1.12 1.14 2.21 2.22 1.41
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Table S5 Transcripts unaffected by No-AS virus infection that are up-regulated by ET-1 with signiﬁcantly increased expression in control cells by Atf3
knockdown
*IEG; **non-IEG.
Control ET-1
Transcript cluster Gene symbol Raw values No virus No-AS AS-Atf3 No virus No-AS AS-Atf3
Cluster C
7305953 Arl4a 482 1 1.07 1.69 1.60 1.99 1.61
7301400 Bdkrb2** 104 1 1.09 1.77 1.74 1.98 2.21
7111272 Btg2* 311 1 0.93 1.87 3.66 4.22 3.28
7209338 Ccnl1* 249 1 0.99 1.77 1.69 1.54 2.47
7045969 Cnksr3 166 1 1.14 1.96 1.61 1.63 2.21
7350918 Csrnp1 146 1 1.17 2.42 3.63 3.82 4.59
7044959 Ctgf* 342 1 0.91 3.04 3.85 4.13 5.22
7215359 Cyr61* 407 1 1.04 1.74 5.22 5.40 6.22
7143265 Eaf1 130 1 1.13 1.87 1.56 1.57 2.12
7163221 Edn1* 71 1 1.11 1.78 1.19 1.26 2.42
7147985 Efnb2** 71 1 0.99 1.74 1.42 1.45 2.15
7281135 Epha2* 90 1 1.16 3.52 2.89 3.29 4.32
7297136 Fam110c 55 1 1.09 1.92 3.70 4.75 3.76
7242382 Fjx1 149 1 1.07 1.74 1.74 1.71 2.10
7252051 Flnc** 143 1 0.94 1.47 2.86 2.31 1.80
7162363 Gadd45g* 357 1 0.99 3.33 4.72 4.19 5.92
7174562 Hbegf* 100 1 0.88 2.73 3.90 4.33 3.84
7193413 Hspa4l 63 1 0.93 2.29 1.94 1.48 2.00
7165193 Inhba** 88 1 1.09 2.09 6.95 6.30 6.29
7257290 Lmcd1* 283 1 1.17 4.41 5.84 6.64 5.84
7100653 Mafk* 187 1 1.00 2.06 2.23 2.25 2.36
7068314 Map2k3** 106 1 1.00 1.65 1.91 1.78 1.96
7194351 Mei1/Tsc22d2 149 1 0.99 1.84 2.45 2.43 2.43
7317471 Myc* 156 1 1.02 2.04 2.28 2.34 2.92
7155813 Nﬁl3* 67 1 1.04 2.71 2.57 2.83 3.71
7189518 Plk2* 1457 1 1.15 2.79 2.14 2.65 3.58
7051029 Ppp1r15a 115 1 1.02 1.93 1.57 1.57 2.26
7360736 Ptp4a1 638 1 1.05 2.14 2.39 2.27 2.36
7048738 PVR* 430 1 1.16 2.58 3.64 3.77 3.48
7340175 Rassf1* 163 1 0.99 1.90 1.62 1.68 2.04
7091811 Rcan1 2101 1 1.12 1.77 1.90 1.95 1.95
7331581 Rnd1* 203 1 1.20 3.24 4.78 4.76 3.58
7238766 Rnd3* 311 1 1.01 1.96 1.82 1.56 2.00
7029999 Sertad1* 217 1 1.09 1.86 1.95 2.50 2.39
7279509 Stk40 144 1 1.00 1.64 1.62 1.57 1.75
7075088 Tnfrsf12a* 750 1 1.09 2.75 3.17 3.26 3.77
7106964 Tnfsf18 80 1 0.87 2.02 9.32 6.92 9.29
7199859 Tspan5** 217 1 1.08 1.69 2.30 2.02 1.95
7120783 Unknown 93 1 0.92 1.47 1.64 1.52 1.55
7339862 Unknown 185 1 0.84 1.53 1.62 1.14 1.60
7085544 Vgll3 133 1 0.96 1.59 2.87 2.52 2.78
7228236 Xirp2 124 1 0.93 2.14 3.84 2.73 2.17
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Table S6 Transcripts affected by No-AS virus infection that are up-regulated by ET-1 and regulated by Atf3
*IEG; **non-IEG.
Control ET-1
Transcript cluster Gene symbol Raw values No virus No-AS AS-Atf3 No virus No-AS AS-Atf3
(a) AS-Atf3 enhances response to ET-1
Cluster D
7120521 Lif* 82 1 1.75 3.70 2.88 3.62 7.30
7106132 Ptgs2* 136 1 1.92 3.93 4.94 4.44 9.84
7237652 Slc25a25* 94 1 1.22 1.71 1.41 1.64 2.19
7028549 Il11 143 1 1.20 1.74 2.88 2.82 3.87
7284153 Ripk2** 238 1 1.31 2.79 2.53 2.72 3.58
7261019 Sema3c 208 1 1.22 2.16 1.67 1.80 2.21
7035407 Wee1 303 1 1.21 1.89 1.74 2.23 2.26
7096947 Zfand2a* 288 1 1.23 1.60 1.73 2.17 2.39
(b) AS-Atf3 inhibits response to ET-1
Cluster E
7259100 Apold1 533 1 0.82 0.63 1.64 1.43 1.02
7105894 B3galt2 505 1 0.79 1.12 2.31 1.97 1.07
7051386 Csrp3 1062 1 0.75 0.72 1.53 1.37 0.72
7084788 Socs3 229 1 1.25 1.01 1.75 1.64 0.77
7370997 Unknown 313 1 0.69 0.81 1.83 1.43 0.80
7135004 Unknown 194 1 0.62 1.24 2.47 2.47 1.40
7305661 Unknown 81 1 0.80 1.25 3.46 3.56 2.12
Table S7 Transcripts that are down-regulated by ET-1 and regulated by Atf3
Control ET-1
Transcript cluster Gene symbol Raw values No virus No-AS AS-Atf3 No virus No-AS AS-Atf3
(a) AS-Atf3 enhances response to ET-1
Cluster F
7279127 Cited4 231 1 0.91 0.48 0.52 0.59 0.47
7180333 Ednra 2175 1 0.99 0.60 0.58 0.64 0.41
7115625 G0s2 2545 1 0.86 0.49 0.30 0.26 0.12
7190436 Lifr 390 1 0.88 0.55 0.60 0.54 0.37
7269707 Ntf3 250 1 1.18 0.54 0.52 0.65 0.37
(b) AS-Atf3 inhibits response to ET-1
Cluster G
7222734 Ddit4 1553 1 1.16 2.04 0.46 0.55 0.79
7120384 Pik3ip1 339 1 0.83 0.57 0.29 0.34 0.46
7346730 Smad6 266 1 1.05 1.41 0.50 0.57 1.03
7197113 Txnip 2024 1 0.90 1.10 0.32 0.39 0.96
7173133 Unknown 690 1 0.74 0.15 0.23 0.16 0.18
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